300 related articles for article (PubMed ID: 37727728)
1. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports.
Khedr A; Hennawi HA; Khan MK; Eissa A; Mir M; Rauf I; Nitesh J; Surani S; Khan SA
World J Clin Cases; 2023 Aug; 11(24):5700-5709. PubMed ID: 37727728
[TBL] [Abstract][Full Text] [Related]
2. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
3. A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
Patel K; Nair A
Cureus; 2022 Sep; 14(9):e29652. PubMed ID: 36320965
[TBL] [Abstract][Full Text] [Related]
4. A Case of Prolonged Recovery for Post-percutaneous Coronary Intervention (PCI) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a 28-Year-Old.
Petersen C; Gyabaah F; Sotelo J; Yohanna S; Deoker A
Cureus; 2023 Sep; 15(9):e45180. PubMed ID: 37842482
[TBL] [Abstract][Full Text] [Related]
5. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors.
Vitale RJ; Valtis YK; McDonnell ME; Palermo NE; Fisher NDL
AACE Clin Case Rep; 2021; 7(1):10-13. PubMed ID: 33521255
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier's gangrene: A case report.
Lindsay PJ; Gibson LE; Bittner EA; Berg S; Chang MG
Int J Surg Case Rep; 2020; 77():463-466. PubMed ID: 33395826
[TBL] [Abstract][Full Text] [Related]
7. COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report.
Batista DV; Vieira CAFA; Costa TA; Lima EG
Diabetol Int; 2021 Jul; 12(3):313-316. PubMed ID: 33133998
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
9. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.
Dutta S; Kumar T; Singh S; Ambwani S; Charan J; Varthya SB
J Family Med Prim Care; 2022 Mar; 11(3):927-940. PubMed ID: 35495849
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
11. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
Sarno MJF; Hernandez DPF; Matulac MO
Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports.
Juneja D; Nasa P; Jain R; Singh O
World J Diabetes; 2023 Aug; 14(8):1314-1322. PubMed ID: 37664476
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
Mistry S; Eschler DC
AACE Clin Case Rep; 2021; 7(1):17-19. PubMed ID: 33851013
[TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
15. A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery.
Osafehinti DA; Okoli OJ; Karam JG
AACE Clin Case Rep; 2021; 7(1):20-22. PubMed ID: 33851014
[TBL] [Abstract][Full Text] [Related]
16. Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights.
Baek HS; Jeong C; Yang Y; Lee J; Lee J; Lee SH; Cho JH; Sohn TS; Son HS; Yoon KH; Lee EY
Diabetes Metab J; 2024 Jun; ():. PubMed ID: 38853537
[TBL] [Abstract][Full Text] [Related]
17. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
Goto S; Ishikawa JY; Idei M; Iwabuchi M; Namekawa M; Nomura T
Am J Case Rep; 2021 Mar; 22():e929773. PubMed ID: 33723205
[TBL] [Abstract][Full Text] [Related]
18. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N
J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592
[TBL] [Abstract][Full Text] [Related]
19. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
Horii T; Oikawa Y; Atsuda K; Shimada A
J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports.
Altowayan WM
Ann Med Surg (Lond); 2022 Dec; 84():104879. PubMed ID: 36582864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
